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undergoing endovascular abdominal aortic
aneurysm repair
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Giovanni Torsello, MD, and Konstantinos P. Donas, MD, Muenster, Germany
Objective: Several studies have conﬁrmed the excellent early performance of the Endurant (Medtronic Endovascular, Santa
Rosa, Calif) endoprosthesis to treat abdominal aortic aneurysms (AAAs). However, data about the long-term durability
of the device are still lacking. We conducted this prospective two-center single-arm study to assess the late outcomes of the
endograft in patients undergoing AAA repair.
Methods: An intention-to-treat analysis was performed for all comers with AAAs who were implanted with an Endurant
endograft between November 2007 and December 2010. Clinical and radiologic data were prospectively collected and
analyzed. The primary end point was any AAA-related reintervention. Secondary end points were overall mortality,
aneurysm shrinkage, all types of endoleak, and device-related complications.
Results: During the study period, 273 patients underwent implantation of the Endurant stent graft. The median follow-
up time for the primary end point was 42 months (interquartile range, 30.7-50.7). AAA-related reinterventions were
required in 26 patients (10%), resulting in a reintervention-free probability of 93%, 90%, and 87% at 3, 4, and 5 years,
respectively. The leading cause for reintervention was iliac limb occlusion (n[ 10). Only one AAA-related death (0.3%)
was reported within an overall mortality of 29% (n [ 78). The median aneurysm shrinkage was 9 mm (interquartile
range, 3-15). Five type I (2%) and one type III (0.4%) endoleaks were identiﬁed. No proximal and two distal limb mi-
grations (1%) were observed.
Conclusions: Our study conﬁrms late durability of the Endurant endoprosthesis for AAA repair, with very encouraging
freedom from reintervention rates and overall outcomes. (J Vasc Surg 2014;60:1125-31.)Although different randomized controlled trials and
meta-analyses have shown comparable survival rates be-
tween open and endovascular repair of abdominal aortic
aneurysms (AAAs), the issue of higher reintervention rates
in endovascular AAA repair (EVAR) has challenged its ef-
ﬁcacy and durability.1-3 Whether these results adequately
reﬂect the on-going transformational progress and reﬁne-
ments of the device design that have expanded the applica-
bility of the EVAR to even more challenging anatomies
remain controversial.4
In this context, the Endurant stent graft (Medtronic
Endovascular, Santa Rosa, Calif) was designed to expandthe Department of Vascular Surgery, St. Franziskus Hospital and
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://dx.doi.org/10.1016/j.jvs.2014.04.070EVAR applicability to challenging AAA anatomy and to
prevent reintervention in the long-term.5 The unique as-
pects of the device are (1) the sinusoidal M-shaped form
of the individual stents, (2) the small amplitude of the
stent graft rings, (3) the active suprarenal ﬁxation, and
(4) the absence of a virtual columnar strength.6 These
characteristics aim to optimize sealing in short and angu-
lated proximal necks by increasing the ﬂexibility and
theoretically preventing the proximal migration of the
endograft.6 The early and midterm evaluation of the de-
vice’s performance revealed encouraging outcomes not
only in friendly but also in challenging anatomic sce-
narios.6-9 A number of series proved also early efﬁcacy
even outside of the instructions for use (IFU).7,10
The literature to date still lacks late results with this
endograft to prove its durability and effectiveness.4 The
aim of this single-arm study was to evaluate the longer-
term performance of the Endurant endoprosthesis in pa-
tients undergoing EVAR in two vascular centers.
METHODS
The design of this study was approved by the local
Ethics Committee (Approval No. 2007-179-f-M) and all
patients provided written informed consent.1125
Table I. Patient characteristics and demographics at time
of endovascular abdominal aortic aneurysm (AAA) repair
(EVAR) with the Enduranta endograft
Variables
No. (%) or mean 6 SD
(N ¼ 273)
Male 246 (90)
Age, years 73 6 9
Comorbidities
Arterial hypertension 226 (83)
Diabetes mellitus 45 (17)
Dyslipidemia 126 (46)
Tobacco use 182 (67)
Coronary artery disease 150 (55)
Myocardial infarction <6 months 89 (33)
Chronic obstructive pulmonary disease 100 (37)
Obesity 88 (32)
Creatinine >1.7 mg/dL 31 (11)
Previous laparotomy 50 (18)
Symptomatic aneurysms 18 (7)
Contained ruptured aneurysms 5 (2)
SD, Standard deviation.
aMedtronic Endovascular, Santa Rosa, Calif.
Table II. Anatomic characteristics and reasons for
implantation outside the instructions for use (IFU) in 79
patients within our study cohort
Characteristics and reasons
Median (range) or
No. (%) (N ¼ 79)
Anatomic characteristics
Angulation, 65 (10-90)
Left iliac artery 45 (15-110)
Right iliac artery 45 (10-90)
Length of proximal neck, mm 9 (7-39)
Maximal AAA diameter mm 57 (40-87)
Proximal neck diameter, mm 26 (17-33)
Reasonsa
Infrarenal angulation >60 and
Neck length >10 mm 31 (39)
Neck length <10 mm 9 (11)
Neck length <10 mm 37 (47)
Reverse tapered proximal neck 32 (41)
Circumferential thrombus at proximal neck 17 (22)
AAA, Abdominal aortic aneurysm.
aIn 13 of 79 patients (16%), the IFU were exceeded in more than one
categories.
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tients undergoing implantation of the Endurant stent
graft for AAA repair between November 2007 and
December 2010 were prospectively collected and
analyzed in an intention-to-treat fashion. The speciﬁc
features of the Endurant stent graft and the procedural
details have been described extensively elsewhere.6 Of
note, a balloon-expandable stent in each limb (by means
of kissing-balloon technique or single placement) was
routinely used in case of a narrow distal aortic neck
(<2.0 cm) or evidence of >70 stenosed Endurant limb
after removal of the stiff wires and performance of the ﬁnal
angiography.
Demographics, comorbidities, and clinical data from all
patients were recorded in a prospective vascular database.
The clinical follow-up included the ﬁndings of the most
current clinical investigation in our outpatient department
or by the attending general practitioner. In addition, a tele-
phone interview with all patients or their relatives was per-
formed to assess survival status. Causes of death were
clariﬁed by contacting the treating general practitioner.
The strict imaging surveillance protocol of EVAR pa-
tients is well standardized in both institutions and previ-
ously published.6 Patients with a glomerular ﬁltration rate
>60 mL/min/1.73 m2 or requiring dialysis underwent
computed tomography angiography (CTA) of the
abdomen before discharge, after 1 year (duplex ultrasound
imaging at 6 months), and then annually up to 5 years in
case of an uncomplicated postinterventional course.
Patients with chronic or acute renal disease (glomerular
ﬁltration rate between 15 and <60 mL/min/1.73 m2) un-
derwent duplex ultrasound imaging and native computed
tomography at the same intervals. In case of AAA-related
symptoms or high suspicion of endoleaks, a magnetic reso-
nance angiography or CTA was performed. Our protocol
for unscheduled CTA in patients with renal disease consists
of (1) hydration with N-acetyl-cysteine before and after the
investigation, (2) consultation by the institution’s nephrol-
ogist, and (3) CTA by contrast agent administration
through a transbrachially placed 5F straight angiographic
Radiofocus catheter (Terumo Medical Corp, Somerset,
NJ). The angiographic catheter is placed at the level of
the proximal descending aorta, and only 20 to 40 mL
contrast agent are used. The straight catheter can be safely
removed in the ward.
End points and deﬁnitions. The primary end point of
the study was any AAA-related reintervention. Secondary
end points included (1) aneurysm shrinkage, (2) occur-
rence of endoleak (all types),3 (3) device-related compli-
cations, including migration and graft/iliac limb occlusion,
and (4) death for any reason during the long-term (overall
mortality).
All measurements before EVAR were performed
directly only by vascular surgeons. In the framework of
this study, all postoperative imaging studies were reana-
lyzed by an independent radiologist with advanced experi-
ence in endovascular aortic surgery and two experienced
vascular surgeons.Statistical analysis. For all analyses and graphs, Med-
Calc 9.4.2.0 software (Mariakerke, Belgium) was used.
Categoric variables are presented as percentages, and
continuous variables as mean 6 standard deviation or me-
dian and interquartile ranges (IQRs) or range. Distribution
was assessed by the D’Agostino-Pearson test. Continuous
normally distributed variables were compared with the
t-test for paired samples (AAA shrinkage), and non-
normally distributed variables were compared with the
Mann-Whitney test. The survival- and reintervention-
free probability rates were demonstrated by means of
Kaplan-Meier curves. Cox regression analysis with back-
ward stepwise selection was performed to identify
Fig 1. A, The centerline (green line), calibrated with Aquarius software (TeraRecon, Foster City, Calif), is used to
assess the migration of the distal iliac limb. B, Type Ib endoleak due to aneurysmatic degeneration of both common
iliac arteries. C, Endovascular repair of both iliac arteries with an iliac side branch device (Cook Medical, Bloomington,
Ind).
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point in the long-term. A P value of <.05 was considered
statistically signiﬁcant.
RESULTS
During the study period, 277 patients underwent im-
plantation of an Endurant stent graft. Four patients (1%)
could not be contacted during follow-up (among whom
two live abroad). The ﬁnal study cohort consisted of 273
patients. Table I summarizes demographics and character-
istics of the study cohort at the time of intervention.
The median duration of the initial intervention was
69 minutes (IQR, 60-90 minutes). The device could not
be implanted in one patient due to stenotic iliac vessels,
and the procedure was abandoned (technical success,
99.7%). General anesthesia was used in 34 patients (13%).
Among the study population, 86 patients (48%)
showed a patent inferior mesenteric artery on thepreoperative CTA. Only one patient underwent emboliza-
tion of the inferior mesenteric artery during EVAR. The
reason was the existence of a prominent inferior mesenteric
artery and the inability of the patient to follow our surveil-
lance protocol. Perioperative type II endoleak was detected
in 133 patients (49%).
Table II presents the anatomic characteristics of the 79
patients (29%) who were treated outside of the device IFU
during the study period. The three most common reasons
for the endograft being used outside of the IFU were a
neck length <10 mm (47%), a reverse tapered neck
(41%), and an infrarenal angulation of the proximal neck
>60 (39%). A narrow distal neck, as deﬁned above, was
present in 20 of 273 patients (7%) at the time of stent graft
implantation.
Primary end point. The median clinical follow-up
time for the primary end point was 42 months (IQR,
31-50 months). During the follow-up period, 26 patients
Table III. Indications for reintervention and secondary procedures in 26 patients
Indications No. Secondary procedure No.
Type Ia endoleaka 3 Explantation of the endograft and open repaira 1
Proximal cuff b 1
Chimney endografting and use of Onyxb,c 1
Type Ib endoleak 2 Iliac side branch device 2
Type II endoleak 4 Embolization of the inferior mesenteric artery 3
Open repaird 1
Type III endoleak 1 Implantation of an additional Endurant limbe 1
Renal artery occlusion 1 Chimney endografting (unsuccessful) and iliac-to-renal bypass (no dialysis) 1
Progression of aneurysmal disease distal
(common iliac artery)
1 Iliac side-branch device 1
Limb occlusion 10 Thrombectomy and stenting 6
Cross-over bypass 4
Bowel ischemia 1 Hemicolectomy 1
False aneurysm 1 Overstitch of the common femoral artery 1
Distal popliteal artery embolizatione,f 1 Thrombectomy, distal extension of the iliac limb with Advanta V12 stent graftg 1
Groin infection 1 Vacuum-assisted closure device 1
aCrawford type A aortic dissection.
bAneurysmatic degeneration without migration.
cev3 Endovascular Inc, Plymouth, Minn.
dIn this patient, the type II endoleak could not be identiﬁed in the computed tomography angiography (CTA); due to aneurysm growth, an open repair
conﬁrmed the type II endoleak (lumbar arteries).
eMedtronic Endovascular, Santa Rosa, Calif.
fThrombus distal to the iliac limb of the endograft.
gAtrium Europe, Mijdrecht, Netherlands.
Fig 2. Kaplan-Meier curve presents the reintervention-free prob-
ability in our study cohort (standard error >10% at 49 months).
Table IV. Causes of death in our study cohort
Cause of death Patients (N ¼ 273), No. (%)a
Death 78 (29)
AAA-related 1 (2)
Cardiac 29 (43)
Carcinoma 13 (19)
Pulmonary 14 (21)
Sepsis 6 (9)
Stroke 4 (6)
Suicide 1 (2)
Unknown 10 (13)
AAA, Abdominal aortic aneurysm.
aThe cause of death was known in 68 patients, and the percentages were
calculated with this number.
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reinterventions and the respective secondary procedures
(Fig 1) are summarized in Table III. The freedom from
reintervention rate was 93%, 90%, and 87% at 3, 4, and
5 years, respectively (Fig 2). The Cox regression analysis
revealed that type II endoleak (intraoperatively or post-
operatively identiﬁed), implantation against IFU, periph-
eral vascular disease, and gender were not risk factors for
reintervention. Early reinterventions (<1 year) were per-
formed in 13 of 26 patients (50%) and late secondary
procedures (>4 years) in four of 26 patients (15%).
Secondary end points. The overall mortality was 29%
(n ¼ 78). The causes of death are presented in Table IV.The survival rates during a median follow-up of 43 months
(IQR, 35-59 months) were 77%, 73%, and 67% at 3, 4, and
5 years, respectively (Fig 3). Only one AAA-related death
was observed in the case of the only technical failure to
advance the endograft. The patient was denied open repair
due to severe heart insufﬁciency (New York Heart Asso-
ciation class IV), and the aneurysm ruptured 2 weeks later.
Type Ia and Ib endoleaks were reported in three and
two patients (2%), respectively. Mean time of radiologic
diagnosis of the type I endoleak was at 42 months (IQR,
26-51 months). The diameters of the index common iliac
artery at the time of implantation in the two patients
with type Ib endoleak were 13 and 22 mm, respectively.
Type III endoleak was observed in one patient (0.3%;
Table III) at 10 months. Persistent type II endoleaks
were reported in 26 patients (10%; Table II), with a median
Fig 3. Kaplan-Meier curve presents the probability of survival in
our study cohort (standard error >10% at 57 months).
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6-39 months).
Mean aneurysm shrinkage was 9 mm (IQR, 3-15 mm;
P < .0001; Figs 4 and 5). Aneurysm shrinkage >5 mm was
observed in 158 patients (58%; Fig 4). Patients with aneu-
rysm shrinkage >5 mm also lived statistically signiﬁcantly
longer than these without shrinkage during the surveillance
period, with a median survival time of 45 months (IQR,
39-54 months) vs 37 months (IQR, 13-47 months;
P < .0001). Device-related complications consisted of iliac
limb thrombosis in 10 (4%) and distal migration in two pa-
tients (1%; Table III). No patients required operations due
to stent graft infection.
DISCUSSION
Numerous studies have shown excellent early out-
comes and rates of technical success with the Endurant
endograft for AAA repair.5-13 We have already published
outcomes at 2 years with this endograft in a part of the pre-
sent study cohort.6 However, a particular scepticism about
the durability of the device has been expressed, considering
the high rates of EVAR-related reinterventions in all ran-
domized controlled trials of EVAR compared with open
repair.1-4 To contribute to the debate, we conducted this
retrospective analysis of our prospectively collected data
to assess the late performance of the Endurant stent graft.
To our knowledge, the present article represents the largest
series of patients to date treated by the Endurant device for
the mentioned study period reporting on late clinical and
radiologic outcomes. Our results showed an excellent dura-
bility of the device, with a reintervention-free probability of
93%, 90%, and 87% at 3, 4, and 5 years, respectively.
Our overall reintervention rates (10%) were lower
compared with the reported secondary procedures in all
randomized controlled trials.1-3 However, we acknowledge
that the study period, the number of centers, and the de-
vices used in the randomized trials are totally different
from our study design, where only one stent graft of thelast generation was tested. The reintervention-free survival
rates in Dutch Randomised Endovascular Aneurysm Man-
agement (DREAM) trial at 5 years were <80% with re-
ported 6-year rates of 70%.1 The Veterans Affairs Open
vs Endovascular Repair (OVER) trialists reported 22% rein-
tervention rates after a mean follow-up of 5.2 years.2
Similar reintervention rates of 23% were observed by the
Comparison of Endovascular Aneurysm Repair with
Open Repair in Patients with Abdominal Aortic Aneurysm
(EVAR) trialists after a median follow-up time of 6 years.3
An additional ﬁnding in our study was that implanta-
tion of the device against the IFU seems not to be a risk
factor for reintervention, conﬁrming our already 1-year
published experience.10 Of note, the shortest proximal
neck length and the maximum proximal neck diameter
treated by means of EVAR in this cohort were 7 mm and
33 mm, respectively. In case of shorter neck lengths, we
advocate open repair in ﬁt patients and fenestrated or
chimney endografting in asymptomatic or symptomatic
high-risk patients, respectively. Our algorithm has been
previously published.12 Furthermore, in case of a symp-
tomatic presentation, aneurysms <5 cm were also endo-
vascularly repaired.
In our study cohort, 50% of the secondary procedures
were performed during the ﬁrst year after EVAR. Two pa-
tients showed a late type Ib endoleak, one at 49 months
and the other at 53 months, due to progression of the
aneurysmatic disease at the level of the common iliac ar-
teries (Fig 1). One type Ia endoleak was diagnosed at
3 months; in this patient, the endograft was placed outside
of the IFU (8 mm proximal neck length, reverse tapered
neck). Two type Ia endoleaks were also diagnosed at 51
and 54 months after EVAR, one due to progression of
the aneurysmatic disease at the level of the suprarenal aorta
and one due to a Crawford type A dissection. In both pa-
tients, the implantation was performed inside the IFU. All
late endoleaks were asymptomatic and ﬁrst identiﬁed
thanks to our strict surveillance and imaging protocol.
Another important ﬁnding was the limb/branch occlu-
sion. Although the rate of occlusion was low (4%), it still
remains the leading cause for reintervention. A similar oc-
clusion rate of 4% (20 patients) was also shown by van Zeg-
geren et al14 in 496 patients with the Endurant stent graft
and a median follow-up of 1.7 years. Limb occlusion rates
seem to be similar (w4%) between the studies, regardless
the type of the device.
Currently, Cieri et al15 reported 40 occlusions (3%) in
1450 different endovascular devices for AAA repair (83
Endurant stent grafts) during a comparable median follow-
up of 45 months. Verhoeven et al16 observed a 4% (n ¼
16) limb occlusions/kinking rate during a mean follow-up
of 40 months in 365 patients with the Talent (Medtronic)
endograft. In contrast to all other studies, Bos et al17 found
no graft limb occlusion with the Gore Excluder (W. L. Gore
and Associates, Flagstaff, Ariz) in 92 selective cases (not all
comers) during a median follow-up of 36 months.
In our analysis, implantation against IFU or peripheral
vascular disease could not be identiﬁed as risk factors for
Fig 4. Computed tomography imaging (CTA) shows impressive aneurysm shrinkage 3 years after implantation of the
Endurant (Medtronic Endovascular, Santa Rosa, Calif) stent graft. A, Preoperative CTA shows a 6-cm abdominal
aortic aneurysm (AAA) without thrombus. B, Postoperative CTA after endovascular repair and before discharge. C,
Postoperative CTA at 3 years shows the complete shrinkage of the aneurysm.
Fig 5. Box-and-whisker plot shows aneurysm diameter before and
after endovascular aneurysm repair (EVAR) at the last follow-up in
overall study cohort. The horizontal line in the middle of each box
indicates the median; the top and bottom borders of the box mark
the 75th and 25th percentiles, respectively, and the whiskers mark
the 90th and 10th percentiles. The circles and red squares mark
outliers.
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the distal end of the iliac limbs is not always in an optimal
apposition to the vessel wall of a tortuous or heavily calci-
ﬁed iliac artery, causing a form of high-grade stenosis or
local vessel damage with intimal hyperplasia. This might
be a reason of limb thrombosis in the long-term, but this
hypothesis should be further investigated and proved.
Meanwhile, we have changed our policy by routinely
relining the distal limbs of the device with an additional
self-expanding stent in cases of tortuous or with a
balloon-expandable stent in case of heavily calciﬁed iliac ar-
teries. Our aim is to achieve a gradual transition of the stent
graft to the iliac anatomy and to conﬁgure a conic shape of
the distal end of the Endurant limb.18 Noteworthy is that
the literature lacks data about the effect of the distal neckon limb patency, and this issue was outside of the topics
of this study.
Impressing indeed was the rate of aneurysm shrinkage
(Figs 4 and 5). Aneurysm shrinkage >5 mm was observed
in 58% of our patients. Houbballah et al19 showed that
AAA shrinkage >5 mm after EVAR is associated with sta-
tistically signiﬁcantly longer survival. This was also
conﬁrmed in our study, where the median survival time
of patients with aneurysm shrinkage >5 mm was 8 months
longer (P < .0001). In contrast to our study, Cieri et al15
found lower but still comparable rates of aneurysm
shrinkage of 40% (33 of 83 patients) in the Endurant
group. However, their study did not report the exact
follow-up time in patients receiving this speciﬁc device.
The migration rate of the Endurant endograft was also
very low in this cohort (n ¼ 2 [1%]), and no proximal mi-
grations were reported. The progression of the aneurys-
matic disease at the level of the common iliac arteries was
the main reason (Fig 1). Compared with the predecessors,
the AneuRx (Medtronic) and Talent endografts, the addi-
tion of the active suprarenal ﬁxation seems to solve the past
issue of high proximal migration rates of 6% reported by
Verhoeven et al16 investigating the Talent endoprosthesis.
Of note, Bos et al17 observed 3% type I endoleak and 2%
migration with the Gore Excluder.
The last outcome analyzed in this study was the sur-
vival of our patients, with survival rates of 77%, 73%, and
67% at 3, 4, and 5 years, respectively. Similar trends were
also observed in the randomized trials as well as in most
retrospective studies.1-3,15,16 In contrast to the randomized
trials, we report no device-related deaths and only one
AAA-related death caused by unsuccessful stent graft im-
plantation. Nevertheless, the survival rates are very encour-
aging considering that we have included all consecutive
patients, including many multimorbid patients unﬁt for
open repair.
This study has some limitations. The design was non-
randomized, and no control arm was used. Despite the
prospective design, the cause of death remained unknown
JOURNAL OF VASCULAR SURGERY
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not be deﬁnitely excluded in those patients, and this could
be a bias of our study. Furthermore, the focus for the
sepsis-related multiple organ failure in six patients was
not conﬁrmed. Considering that all six patients had pneu-
monia at admission, we did not count them as graft-related
complications. Finally, no volumetric analysis of the aortic
thrombus and no assessment of the severity of calciﬁcation
and tortuosity were performed; thus, their exact effect on
the outcomes could not be assessed and was outside of
the topics of this study.
CONCLUSIONS
This study presents very promising late outcomes with
the Endurant endograft for endovascular AAA repair. The
results showed high freedom from reintervention rates, low
rates of type I or III endoleaks, no proximal migration, and
an impressive rate of aneurysm shrinkage in more than the
half of the patients. Iliac limb occlusions rates are compara-
ble with other devices and remain the leading cause of rein-
tervention. The pathogenesis of iliac limb occlusion after
EVAR requires further investigation. In any case, the re-
sults of this study conﬁrm our hypothesis about the excel-
lent late performance and durability of the Endurant
endoprosthesis.
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